Cefatrizine

Cefatrizine (BL-S-640) is an orally active and broad-spectrum cephalosporin antibiotic. Cefatrizine is also a eEF2K inhibitor, with anti-proliferative activity in human breast cancer cells, which could induce ER stress, leading to cell death. Cefatrizine can be used in studies of cancer and bacterial infection^[1][2]. IC50 & Target:eEF2K, bacterial^[1][2]. In Vitro:Cefatrizine (0-100 µM; 24 h) causes a remarkable anti-proliferative effect on MCF-7 and MDA-MB-436 cell growth in a dose-dependent manner^[1].
Cefatrizine (30 µM; 12 h) induces ER stress in breast cancer cells^[1].
Cefatrizine (12, 24, 36 h) increases level of CHOP (marker of ER stress induced apoptosis) and promotes expressions of core proteins in eEF2K-modulated ER stress pathways (Bip, p-PERK, XBP-1S and p-JNK) in MCF-7 and MDA-MB-436 cells^[1]. In Vivo:Cefatrizine (BL-S-640) (0.2, 1, 5, 25 mg/kg; p.o.; 4 times daily for 3 days) reduces the number of infecting organisms in the bladder and the kidneys in P. mirabilis intracystically infected model^[2].